The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.
We have reported previously that despite treatment with angiotensin-converting enzyme inhibitors and beta blockers, the outcome of patients with peripartum cardiomyopathy (PPC) remains unfavorable. Similar to other etiologies of left ventricular dysfunction, we found elevated levels of tumor necrosis factor-alpha (TNF-alpha) in this group of patients. In the present study we sought to evaluate the effects of pentoxifylline, a drug known to inhibit the production of TNF-alpha, on clinical status, left ventricular function, and circulating plasma levels of TNF-alpha, in patients with PPC. We followed prospectively 59 consecutive women with PPC. The first 29 patients (group 1) were treated with diuretics, digoxin, enalapril and carvedilol. The next 30 consecutive patients (group 2) received pentoxifylline 400 mg TID in addition to the previous therapy. Clinical evaluation, echocardiograms and TNF-alpha determinations were performed at baseline and after 6 months of treatment. Patients in the pentoxifylline group were older and had a higher E/A ratio. Nine patients died (eight in group 1, P = 0.009 between groups). A combined end-point of poor outcome defined as either death, failure to improve the left ventricular ejection fraction >10 absolute points or functional class III or IV at latest follow-up, occurred in 52% of patients in group 1 and 27% of patients in group 2 (P = 0.03). Treatment with pentoxifylline (P = 0.04) was the only independent predictor of outcome. In conclusion, the results of this study suggest that the addition of pentoxifylline to conventional treatment, improves outcome in patients with peripartum cardiomyopathy.
Sliwa
Karen
K
Department of Cardiology, Baragwanath Hospital, University of the Witwatersrand, PO Bertsham 2013, Johannesburg, South Africa. hahnle@netactive.co.za
Skudicky
Daniel
D
Candy
Geoffrey
G
Bergemann
Anette
A
Hopley
Mark
M
Sareli
Pinhas
P
D000328:Adult; D009202:Cardiomyopathies / Q000097:blood / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010431:Pentoxifylline / Q000627:therapeutic use*; D011247:Pregnancy; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000097:blood / Q000188:drug therapy*; D012044:Regression Analysis; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000188:drug therapy*
D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline